Kezar Life Sciences, Inc.
KZR
$4.50
$0.102.27%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -20.22M | -20.31M | -21.55M | -21.66M | -32.26M |
| Total Depreciation and Amortization | 259.00K | 260.00K | 261.00K | 260.00K | 280.00K |
| Total Amortization of Deferred Charges | 66.00K | 64.00K | 65.00K | 64.00K | 59.00K |
| Total Other Non-Cash Items | 2.40M | 1.96M | 3.25M | 1.92M | 4.60M |
| Change in Net Operating Assets | 668.00K | 536.00K | 945.00K | -3.45M | 8.35M |
| Cash from Operations | -16.83M | -17.49M | -17.03M | -22.86M | -18.98M |
| Capital Expenditure | -11.00K | -18.00K | -- | -- | -1.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 23.76M | 24.08M | 12.22M | 20.41M | 27.88M |
| Cash from Investing | 23.74M | 24.06M | 12.22M | 20.41M | 27.88M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 47.00K | 0.00 | 56.00K | -- | 59.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 47.00K | 0.00 | 56.00K | -- | 59.00K |
| Foreign Exchange rate Adjustments | -75.00K | 16.00K | 3.00K | -7.00K | 38.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.89M | 6.58M | -4.76M | -2.46M | 9.00M |